GLAXF News and Press, GlaxoSmithKline Plc From 07/09/22

Pfizer has a pipeline with more than 90 drugs in development. Pfizer is developing two drugs capable of generating more than a billion sales. Competition is fierce but Pfizer is in the race. Pfizer's story of success Pharmaceutical giant Pfizer ( PFE ) is one of ...

The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names. It's clear (to us) that AUPH should be on the ...

Unilever's brands are positioned well to navigate whatever is to come economically, it has already grown 7.3% in Q1 in response to inflation. The impact of inflation will reduce profits but on a relative basis, Unilever will become more attractive. 5 years of stagnation has left U...

My portfolio, built specifically for my retirement ~20+ years from now, makes a strong bet on a stock due for potential FDA approval in July. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valu...

Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...

Arrowhead is a leader in RNAi. ARWR has a vast platform. I will wait for the first approval before investing. For further details see: Arrowhead Pharma: We Can Afford To Wait For More Proof

23andMe is a consumer-facing genetics testing company, one of the largest in terms of genetic databases. However, there are some glaring financial risks to consider if you want to invest in the company: slow test kit growth and profitability. New attempts to move towards drug deve...

Start Time: 09:45 End Time: 10:18 GSK plc (GSK) dbAcess Global Consumer Conference June 14, 2022, 09:45 AM ET Company Participants Tobias Hestler - CFO GSK Consumer Healthcare Conference Call Participants Tom Sykes - Deutsche Bank Presentation Tom Sykes Good afternoon, everybody, and thank yo...

Results from the phase 3 INFRONT-3 study using AL001 for the treatment of patients with Frontotemporal dementia are expected in 2023. Alector holds the potential to advance AL001 for both FTD-GRN and FTD-C9orf72 patients, plus several other neurological indications like Alzheimer's Di...

GSK has been a stalwart of stability in the healthcare sector, despite the lack of growth. Q2 2022 performance stood out, and performance has been strong across the board. The company is undergoing transformational changes that will make the investment proposition different, hopef...